NOVO B Share Price Performance
DKK 0
-773.90 (-100.00%)
Price DKK 0
Fair ValueDKK 431.99
Share Pricen/a
Novo Nordisk A/S Stock Price
- 5 Narratives written by author
- 21 Comments on narratives written by author
- 1243 Fair Values set on narratives written by author
NOVO B Community Narratives
AN
Fair Value DKK 431.99 31.8% undervalued intrinsic discount
Product Launches And Leadership Shifts Will Support Expanding Market Reach
10users have liked this narrative
3users have commented on this narrative
467users have followed this narrative
AN
Fair Value DKK 340 13.3% undervalued intrinsic discount
Regulatory And Generic Challenges Will Compress Margins But Uplift Pipeline
1users have liked this narrative
0users have commented on this narrative
21users have followed this narrative
TO
Fair Value DKK 851.04 65.4% undervalued intrinsic discount
EU#2 - From Humble Beginnings to Global Powerhouse
21users have liked this narrative
11users have commented on this narrative
64users have followed this narrative
EU#2 - From Humble Beginnings to Global Powerhouse
Novo Nordisk, one of the world’s leading pharmaceutical companies, has a unique and inspiring origin story rooted in personal tragedy and scientific curiosity. The company’s roots date back to the 1920s, when Danish Nobel laureate August Krogh, a renowned physiologist, and his wife Marie, who suffered from type 2 diabetes, traveled to Canada.Read more
21users have liked this narrative
11users have commented on this narrative
64users have followed this narrative
TO
DKK 851.04
65.4% undervalued intrinsic discount
Tokyo Fair Value
Revenue growth
22.49% p.a.
Profit Margin
34.78%
Future PE
24x
Share price in 2029
DKK 1.53k
Novo Nordisk gears up for explosive growth in weight-loss and diabetes treatments
Catalysts Most Immediate Catalyst (1–2 Years): Weight-Loss Drug Boom: Novo Nordisk’s Wegovy (semaglutide) is dominating the obesity drug market , with demand outpacing supply. Obesity treatment is becoming a major new revenue stream.Read more
18users have liked this narrative
7users have commented on this narrative
43users have followed this narrative
UN
DKK 1.04k
71.6% undervalued intrinsic discount
Unike Fair Value
Revenue growth
10% p.a.
Profit Margin
40%
Future PE
30x
Share price in 2029
DKK 1.29k
Product Launches And Leadership Shifts Will Support Expanding Market Reach
Key Takeaways Vast global demand for GLP-1 therapies and metabolic disease treatments offers long-term revenue growth, as adoption and access increase amid rising obesity and aging trends. Expanded product launches, manufacturing investments, and innovation in new disease areas are set to boost market reach, support resilient earnings, and reduce supply constraints.Read more
10users have liked this narrative
3users have commented on this narrative
467users have followed this narrative
AN
DKK 431.99
31.8% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
5.41% p.a.
Profit Margin
34.3%
Future PE
17.46x
Share price in 2028
DKK 501.18
Regulatory And Generic Challenges Will Compress Margins But Uplift Pipeline
Key Takeaways Heavy reliance on blockbuster therapies and looming patent expirations expose Novo Nordisk to revenue pressure from biosimilar competition and pricing headwinds. Expanding international demand is offset by rising economic inequality, regulatory risks, and escalating operating costs, threatening long-term growth and margins.Read more
1users have liked this narrative
0users have commented on this narrative
21users have followed this narrative
AN
DKK 340
13.3% undervalued intrinsic discount
AnalystLowTarget Fair Value
Revenue growth
4.5% p.a.
Profit Margin
33.85%
Future PE
14.39x
Share price in 2028
DKK 392.59
Urbanization And Aging Trends Will Amplify GLP-1 Adoption
Key Takeaways International expansion and supply ramp-up position the company for robust, sustained growth by unlocking untapped patient pools and converting demand into profit. Innovation in pipeline, digital health leadership, and streamlined operations broaden revenue streams and boost efficiency, strengthening dominance in chronic disease management.Read more
0users have liked this narrative
0users have commented on this narrative
19users have followed this narrative
AN
DKK 612
51.8% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue growth
13.45% p.a.
Profit Margin
36.77%
Future PE
18.64x
Share price in 2028
DKK 706.66
Snowflake Analysis
Novo Nordisk A/S Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Feb 04, 2026
- 23.35
- 82.35%
- 32.88%
- 59.6%
About NOVO B
- Founded
- 1923
- Employees
- 78554
- CEO
- WebsiteView website
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.